US 11,918,548 B2
Treatment of avascular or hypovascular micro-tumors
Yicheng Ni, Herent (BE)
Assigned to Katholieke Universiteit Leuven, Leuven (BE)
Appl. No. 16/628,904
Filed by Katholieke Universiteit Leuven, Leuven (BE)
PCT Filed Jul. 4, 2018, PCT No. PCT/EP2018/068141
§ 371(c)(1), (2) Date Jan. 6, 2020,
PCT Pub. No. WO2019/008064, PCT Pub. Date Jan. 10, 2019.
Claims priority of application No. 1710936 (GB), filed on Jul. 7, 2017; and application No. 100362 (LU), filed on Aug. 7, 2017.
Prior Publication US 2020/0138739 A1, May 7, 2020
Int. Cl. A61K 31/09 (2006.01); A61K 9/00 (2006.01); A61K 31/122 (2006.01); A61K 31/42 (2006.01); A61K 31/661 (2006.01); A61K 33/18 (2006.01); A61P 35/00 (2006.01)
CPC A61K 31/09 (2013.01) [A61K 9/0019 (2013.01); A61K 31/42 (2013.01); A61K 31/661 (2013.01); A61P 35/00 (2018.01); A61K 31/122 (2013.01); A61K 33/18 (2013.01)] 9 Claims
OG exemplary drawing
 
1. A method of treating an avascular tumor or hypovascular tumor with a diameter less than 20 mm comprising the step of administering an effective amount of a vascular disrupting agent (VDA) or salt or solvate or prodrug thereof, wherein the VDA is a combretastatin, and wherein the avascular tumor is not metastatic or the hypovascular tumor is not metastatic.